KNC Laboratories Co. Ltd., Dainippon Sumitomo, Kobe University deal

On Dec. 27, 2012, Dainippon received exclusive, worldwide rights to cancer compounds targeting the Ras pathway that were discovered by R&D and manufacturing services company KNC and the university. Under the deal, Dainippon will assume development, manufacturing and sales activities. KNC and Kobe will receive an upfront payment and are eligible for milestones and royalties. The partners did not disclose financial terms. ...